These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19736617)

  • 1. The importance of target validation in drug discovery and development.
    Lowe JA; Jones P; Wilson DM
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):581-4. PubMed ID: 19736617
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correct assessment of new compounds using in vivo screening models can reduce false positives.
    Bueters TJ; Hoogstraate J; Visser SA
    Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-induced long QT syndrome].
    Kishida H
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():426-9. PubMed ID: 18074575
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological MRI: a biomarker in CNS drug discovery and development?
    Lucignani G; Bastianello S
    Funct Neurol; 2007; 22(2):71-3. PubMed ID: 17637208
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug-induced sexual and gonadal disorders].
    Katabami T; Iwamoto T
    Nihon Rinsho; 2006 Jun; Suppl 2():321-5. PubMed ID: 16817413
    [No Abstract]   [Full Text] [Related]  

  • 8. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smaller is better for antibiotic discovery.
    Waldrop GL
    ACS Chem Biol; 2009 Jun; 4(6):397-9. PubMed ID: 19537754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?
    Dyson A; Singer M
    Crit Care Med; 2009 Jan; 37(1 Suppl):S30-7. PubMed ID: 19104223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication effects on metabolic rate: a systematic review (part 2).
    Dickerson RN; Roth-Yousey L
    J Am Diet Assoc; 2005 Jun; 105(6):1002-9. PubMed ID: 15942556
    [No Abstract]   [Full Text] [Related]  

  • 13. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
    Singh M; Johnson L
    Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
    Tian X; Switzer AG; Derose SA; Mishra RK; Solinsky MG; Mumin RN; Ebetino FH; Jayasinghe LR; Webster ME; Colson AO; Crossdoersen D; Pinney BB; Farmer JA; Dowty ME; Obringer CM; Cruze CA; Burklow ML; Suchanek PM; Dong L; Dirr MK; Sheldon RJ; Wos JA
    J Med Chem; 2008 Oct; 51(19):6055-66. PubMed ID: 18771254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine.
    Vidalin O; Muslmani M; Estienne C; Echchakir H; Abina AM
    Curr Opin Pharmacol; 2009 Oct; 9(5):669-76. PubMed ID: 19646923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
    Rossi T; Braggio S
    Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.
    Elangbam CS
    Vet Pathol; 2009 Jan; 46(1):10-24. PubMed ID: 19112110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental biology 2006: advancing the biomedical frontier.
    Edwards C
    IDrugs; 2006 Jun; 9(6):402-4. PubMed ID: 16752307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.